| ACOSOGTHOC140503 | A Phase III Randomized Trial of Lobectomy versus Sublobar Resection for Small (less than or equal to 2 cm) Peripheral Non-Small Cell Lung Cancer | Open |
| CTSUTHOC30607-M | ARandomized, Phase III, Double-Blind Placebo-Controlled Trial of Sunitinib as Maintenance Therapy in Non-Progressing Patients following an Initial Four Cycles of Platinum-Based Combination Chemotherapy in Advanced, Stage IIIB/IV Non-Small Cell Lung Cancer | Open (affiliates only) |
| ECOGTHNE5508 | Randomized Phase III Study of Maintenance Therapy with Bevacizumab, Premetrexed, or Combination of Bevacizumab and Premtrexed following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC | Open |
| ECOGTHO4508-M | Three-Arm Randomized Phase II Study of Carboplatin and Paclitaxel in
Combination with Cetuximab, IMC-A12 or Both for Advanced Non-small Cell Lung Cancer Patients WhoWill Not Receive Bevacizumab-based Therapy | Open (affiliates only) |
| ECOGTHO5508-M | Randomized Phase III Study of Maintenance Therapy with Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC | Open (affiliates only) |
| ECOGTHOE1505 | A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB (>=4 cm)-IIIA Non-Small Cell Lung Cancer (NSCLC). | Open |
| ECOGTHOE1505-M | A Phase III Randomized Trial of Adjuvant Chemotherapy with or without Bevacizumab for Patients with Completely Resected Stage IB (> or = 4 cm)- IIIA Non-Small Cell Lung Cancer (NSCLC) | Open (affiliates only) |
| PRECOGTHO0501-M | A Randomized Phase II Study Evaluating Vandetanib (ZD6474) in Combination with Doecetaxel and Carboplatin+/-Placebo or Maintenance Therapy with Vandetanib in Patients with IIIb, IV, or Recurrent Non-Small Cell Lung Cancer | Open (affiliates only) |
| VICCHN0908 | Comparison of Biomarker Modulation by Inhibition of EGFR and/or SRC Family Kinases Using Erlotinib and Dasatinib in Head and Neck and Lung Cancers. | Open |
| VICCREACH1113 | Formative Research Needs to Address the Differing Needs of Cancer Survivors (Pilot #1 of the MMC and VICC Partnering for Survivorship Project) | Open (affiliates only) |
| VICCTHN1119 | Phase 2, Open-Label, Multi-Center Study of Amuvatinib in Combination with Platinum Etoposide Chemotherapy in Small Cell Lung Cancer Subjects who have not Responded to Standard Treatment or Relapsed After Standard Treatment | Open |
| VICCTHN1164 | Molecular Profiles for Lung Cancer Pathogenesis and Detection | Open |
| VICCTHO0136 | Molecular Fingerprinting of Lung Cancer (SPORE) | Open |
| VICCTHO0373 | Identification and Validation of Molecular Markers in Lung Cancer (SPORE) | Open |
| VICCTHO0398 | Molecular Predictors of Lung Cancer Behavior. (SPORE) | Open |
| VICCTHO0547 | Molecular Fingerprints in Lung Cancer: Predicting Tumor Response to Therapy (SPORE) | Open |
| VICCTHO0730 | A Phase II Trial of Celecoxib plus Chemotherapy [Docetaxel or Pemetrexed] in Patients with Previously Treated, "COX Dependent" Recurrent Non-Small Cell Lung Cancer (SPORE) | Open |
| VICCTHO09103 | A Phase Ib Open-Label Clinical Trial of Continuous Once Daily Oral Treatment Using BIBW 2992 Plus Cetuximab (Erbitux) in Patients with Non-Small Cell Lung Cancer with Progression Following Prior Erlotinib (Tarceva) or Gefitinib (Iressa) | Open |
| VICCTHO0920 | Phase II Study of Second-Line Bendamustine in Relapsed or Refractory Small Cell Lung Cancer (SCLC). | Open |
| VICCTHO0938 | Survey and Blood Sample Collection for Patients with Lung Cancer Who Never Smoked Cigarettes. | Open |
| VICCTHO0976 | Molecular Biomarkers of Small Cell Lung Cancer Behaviour | Open |
| VICCTHO1042 | A Phase 1-2 Trial of MM-121 in Combination with Erlotinib in Three Groups of Patients with Non-Small Cell Lung Cancer | Open |
| VICCTHO1078 | Nashville Early Diagnosis Lung Cancer Project | Open |